Acamprosate Safe to Use in Individuals With Liver Disease.

Status Completed

Clinical Trial Summary

Is acamprosate safe to use in individuals with liver disease.

Clinical Trial Description

Adult patients aged 21 or over with a diagnosis of alcohol-related liver disease and alcohol use disorder (AUD) and abstinent from alcohol for at least 2 weeks (but not more than 6 months) prior to initiating acamprosate treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04287920
Study type	Interventional
Source	Mayo Clinic
Contact
Status	Completed
Phase	Phase 2
Start date	September 21, 2020
Completion date	January 5, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04876443` - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Recruiting	`NCT06409130` - Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease	Phase 2
Completed	`NCT01812226` - Alcohol Biomarkers in Post-Liver Transplant Patients
Not yet recruiting	`NCT06305624` - Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease	N/A
Active, not recruiting	`NCT06183710` - Contingency Management to Incentivise Treatment Adherence in Alcohol-related Liver Disease	N/A
Recruiting	`NCT06403332` - Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.	N/A
Not yet recruiting	`NCT05623150` - CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Not yet recruiting	`NCT06269510` - Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients	N/A